Journal Of Translational Medicine Research Articles

Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis.

In recent years, the vaccinia oncolytic virus has entered the clinical trial stage of examination and shown good progress. It has many advantages, such as good safety, high oncolytic efficiency, and the regulation ability of the tumor microenvironment, and is expected to be successfully used in the clinical treatment of tumors in the future. However, no bibliometric analysis has so far been performed that generalizes horizontally across this field. Therefore, this study aims to assess the research status and trends in this field from a global perspective to help guide future research priorities. In this study, the literature related to vaccinia oncolytic virus published in English on Web of Science from 2002 to 2022 was retrieved, and the bibliometric indicators were analyzed using the Histcite. Pro 2.0 tool, while VOSviewer was used to visualize the research trends and hotspots in this field. In total, 408 related studies were included. In the past 20 years, the number of related publications in this field has increased year by year, and breakthroughs were made in this field in 2008 and 2013. The research has grown rapidly since 2008, and will likely continue to expand in the years to come. The United States plays a leading role in this area. "MOLECULAR THERAPY-ONCOLYTICS", "MOLECULAR THERAPY" and "JOURNAL OF TRANSLATIONAL MEDICINE" are core journals that publish high-quality literature on the latest advances in the field. Some authors with numerous high-quality publications include Bell JC and Szalay AA. At present, the research hotspot in this field focus on the clinical application of vaccinia oncolytic virus. Overall, the number of vaccinia oncolytic virus-related studies is growing rapidly, in relation to which the United States is the most influential country. The clinical application of vaccinia oncolytic virus will affect the crucial development of future research.

New study gives F to vitamin C treatment in septic ICU patients

New study gives F to vitamin C treatment in septic ICU patients

International Journal of Translational Medicine: An Interdisciplinary Open Access Journal to Publish Your Biomedical Research with a “Bench-to-Bedside” Approach

The International Journal of Translational Medicine (ISSN 2673-8937) is an open access journal that lays its foundation in a diverse editorial board that takes advantage from the distinctive expertise of the various members [...]

Abstract B151: Exploring the induction of immunogenic cell death (ICD) by high-intensity focused ultrasound (HIFU)

Abstract Immunogenic cell death (ICD) is an intriguing concept within cancer immunotherapy. Indeed, by inducing a specific means of cellular demise, a protective immune response can be triggered against the dying cells. As such, the dying cancer cells are—in a way—turned into a vaccine, attracting immune cells to the site of cell death, and activating them to trigger an anticancer immune response. Since the early discovery of ICD, more mechanistic insights into the hallmarks of ICD have been unraveled and several state-of-the-art cancer therapies have been identified as bona fide ICD inducers (1, 2).One of the cancer therapies which could be a potential candidate to induce ICD is high-intensity focused ultrasound (HIFU) (3). HIFU is currently used as a way of debulking solid tumors in a non-invasive, image-controlled and precise way without the use of ionizing radiation. Depending on the ultrasound parameters, tumor tissue can be ablated either in a mechanical (tissue disruption) or thermal way (heating and coagulative necrosis). Interestingly, there are some indications that HIFU may also affect the immune system: experiments in mice and man have shown attraction/activation of immune cells to/in the tumor site (4, 5). Of note: these immunostimulating effects were reported to be more prominent for mechanical HIFU than thermal HIFU. However, neither the mechanisms behind these observations, nor the possible link to the induction of ICD have been investigated. Therefore, the key aim of work is to investigate the potential of HIFU to induce ICD. Using a custom-designed HIFU set-up, we were able to—in a precise, automated and controlled way—expose B16F0 melanoma cells to HIFU in vitro. The HIFU-exposed tumor cells were subsequently evaluated for the occurrence of apoptosis and ICD hallmarks. More specifically, we evaluated the exposure of calreticulin (CRT) on the cell membrane and release of high mobility group box 1 (HMGB-1) and adenosine triphosphate (ATP). Our data show that application of mechanical HIFU protocols (using short, repeated ultrasound bursts) induce a significant fraction of apoptotic cells (as measured by a loss of mitochondrial membrane potential) within 4h after treatment. Importantly, already within the first hour after HIFU exposure, high levels of the ICD hallmark and Toll-like receptor 4 agonist HMGB-1 were found in the supernatant of the HIFU-treated cells, compared to untreated controls. To determine the effect of HIFU on ATP release, a quinacrine assay was performed to stain intracellular ATP-containing vesicles. Using flow cytometry, we observed that HIFU triggered exocytosis of these vesicles, with 2- to 3-fold reductions in quinacrine fluorescence at 4h and 24h after HIFU exposure, respectively. In addition, at 24h after HIFU exposure, >30% of the cells exposed CRT on the outer leaflet of the cell membrane, which was a drastic increase compared to blanks (<1% CRT exposure). Taken together, these results indicate that 3 key hallmarks of ICD can be detected after treatment of B16F0 melanoma cells with an optimized mechanical HIFU protocol. Currently, vaccination experiments are ongoing to determine whether HIFU-treated cells induce protective immunity in mice. If we could identify mechanical HIFU as a true ICD inducer, this might have important repercussions to how HIFU ablative therapies are applied in the clinic: modified HIFU regimens that not only focus on full ablation, but also trigger ICD could be envisaged to simultaneously tackle primary tumors as well as distant metastasis. Moreover, this could provide a solid basis for the rational combination of HIFU with other immunotherapies to strengthen the evoked immune response.

First results on the DCVax phase III trial: raising more questions than providing answers.

Recently, the long-awaited report on efficacy data of the DCVax trial has appeared in the Journal of Translational Medicine.1 Patients and physicians alike are eager to critically evaluate the first results of this important trial, which is one of the earliest major attempts to improve outcome in patients with glioblastoma using immunotherapy based on an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax). It is not only one of the first randomized phase III trials of its kind, but in light of recent successes with cancer immunotherapies outside neuro-oncology, there is a huge interest in any form of immune treatment for glioma patients.

Introduction to Translational Research for Orthotists and Prosthetists

Introduction to Translational Research for Orthotists and Prosthetists

Abstract 1722: Effectiveness of predictive simulation in identifying potential patient-specific therapeutic targets in multiple myeloma-a pilot study

Abstract Targeting specific constellation of molecular abnormalities through predictive simulation modeling may provide a practical therapeutic approach to this complex disease. Cellworks provides a simulation approach that comprehensively models signal transduction, epigenetic regulation, metabolic, and other regulatory networks in cancer cells. This approach is able to identify a patient's dominant characteristics and enable design of a personalized treatment incorporating the patient's genomic signature. We validated this in patients with glioblastoma1, multiple myeloma2 and polycythemia vera3. In this feasibility study we test personalization methodology by modeling MM patients based on genomic information derived from patient marrow and predict therapeutic targets. The modeling analysis for two MM patients is presented. Cytogenetic analyses indicated massive chromosome aberrations and changes in gene copy numbers (CNV) in both patients. Using this information, 557 and 816 gene perturbations (low and high CNV), respectively, were included to model the patients’ simulation avatar. In the first patient, analysis of the simulation network predicted elevated NFkB levels due to high copy number of NFkB, TRAF1, MYD88, TLR2, TLR6. High levels of ERK, AP1 and beta catenin (CTNNB1) were also detected. In the second patient, a similar analysis predicted increased activation of STAT3/5 signaling due to high CNV of IL6 and IL6ST, JAK3 and JAK2; and low CNV of ETV6 that negatively regulates STAT3/5 signaling. Data also indicated amplification of PI3K/Akt and mToR signaling pathways in both cases. Most importantly, modeling predicted sensitivity to a combination of ERK inhibitor Trematinib with mTOR inhibitor Everolimus and Cyclooxygenase 2 inhibitor Celecoxib in the first patient and sensitivity to a combination of JAK inhibitor Tofacitinib with Everolimus and Celecoxib in the second patient. Based on these actionable insights, 5 MM patients to be profiled for cytogenetic and molecular abnormalities in a pilot study (IRB under review), and thereafter modeled to create patient simulation avatars. A library of FDA-approved drugs from across indications will be simulated against the predicted deregulated pathways to generate predictive drugs with therapeutic potential. In parallel, CD138+ plasma cells will be sorted from the aspirated samples for ex vivo clinical validations with the predicted therapeutic drugs. 1.Pingle S. et al. Journal of Translational Medicine 2014; 12:128; 3. Sayeski, P. et al. ASH 2014 Abstract:3212; 2.Doudican, N. et al. ASH 2014 Abstract: 2232. Citation Format: Sathish Kumar, Shireen Vali, Kabya Basu, Saji Gera, Neeraj Singh, Ansu Kumar, Taher Abbasi, Shazib Pervaiz. Effectiveness of predictive simulation in identifying potential patient-specific therapeutic targets in multiple myeloma-a pilot study. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1722. doi:10.1158/1538-7445.AM2015-1722

Animal models of chronic tympanic membrane perforation: in response to plasminogen initiates and potentiates the healing of acute and chronic tympanic membrane perforations in mice

Tympanic membrane perforations (TMP) are relatively common but are typically not treated in their acute stage, as most will heal spontaneously in 7–10 days. Those cases which fail to heal within 3 months are called chronic TMP which attract surgical intervention (e.g. myringoplasty), typically with a temporalis fascia autograft. New materials for the repair of chronic TMP are being developed to address deficiencies in the performance of autografts by undergoing evaluation in animal models prior to clinical study. However, there is currently a lack of ideal chronic TMP animal models available, hindering the development of new treatments. Various techniques and animal species have been investigated for the creation of chronic TMP with varied success. In the present commentary, we bring to the attention of readers the recent report by Shen et al. in Journal of Translational Medicine. The study reported the creation of a chronic TMP animal model in plasminogen gene deficient mice. However, the short observation time (9, 19 days), lack of success rate and the scarcity of solid evidence (e.g. otoscopic & histologic images) to confirm the chronicity of TMP warrant a more thorough discussion.

Journal of Translational Medicine reviewer acknowledgement 2013

Contributing reviewersThe editors of Journal of Translational Medicine would like to thank all our reviewers who have contributed to the journal in Volume 11 (2013).

Pathogenesis of Chagas Cardiomyopathy: Role of Inflammation and Oxidative Stress

Described by the Brazilian scientist Carlos Chagas more than a century ago, Chagas disease (ChD) currently affects 8 to 10 million persons and causes more than 10 000 deaths each year.[1][1] Originally confined to Latin American countries, ChD had been considered an exotic disease and received less

Retraction Note: Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine

Retraction Note: Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine

Journal of translational medicine reviewer acknowledgement 2012

Contributing reviewersThe editor of Journal of Translational Medicine would like to thank all our reviewers who have contributed to the journal in Volume 10 (2012).

JTM’s Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section

For the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor Immunology and Biological Cancer Therapy. Under the editorial leadership of Dr. Pedro Romero and with the direct support of the Society for Immunotherapy of Cancer (SITC), this section enriched the communication between basic immunological sciences and the clinical investigation arena in oncology. We are re-launching this Section of JTM, now entitled Immunobiology and Immunotherapy, succeeding Tumor Immunology and Biological Cancer Therapy. While aiming to build on the editorial success and focus of its predecessor, this novel Section will have a broader scope, hosting translational immunology topics pertaining to immunotherapy beyond oncology, including disciplines such as inflammation, autoimmunity, transplantation, metabolic disorders and others. As the vision of this re-launched Section of JTM broadens up to serve a communication need for translational immunologists involved with immunotherapy irrespectively of the therapeutic area, a novel and focused journal entitled Journal for Immunotherapy of Cancer (JITC) has just been initiated, sponsored by the SITC.

SOCS2 expression in bone marrow derived dendritic cells is a positive regulator of T cell activation

Dept. of Medicine, Translational Immunology Unit, Karolinska Institutet, Stockholm, Sweden Full list of author information is available at the end of the article Figure 1 The effect of SOCS2 KO, on pro-inflammatory cytokine release in LPS induced BMDCs. BMDCs from WT and SOCS2 mice were stimulated with LPS (100 ng/ml) till 48 hours. mRNA expression of indicated cytokines was measured at the indicated time points. Hu et al. Journal of Translational Medicine 2012, 10(Suppl 3):P19 http://www.translational-medicine.com/content/10/S3/P19

Computational modeling and epidemiologic approaches: a new section of the journal of translational medicine

A new section of the Journal of Translational Medicine is being introduced to encourage rapid communication of methods and results that utilize computational modeling and epidemiologic approaches in translational medicine. The focus will be on population-based studies that extend towards more molecular level analysis. Submission of studies involving methods development is encouraged where actual application and results can be shown in the healthcare and life sciences domains.

Introducing the medical bioinformatics in Journal of Translational Medicine

The explosion of genome sequencing data along with genotype to phenotype correlation studies has created data deluge in the area of biomedical sciences. The aim of the Medical bioinformatics section is to aid the development and maturation of the field by providing a platform for the translation of these datasets into useful clinical applications. The increase in computing capabilities and availability of different data from advanced technologies will allow researchers to build System Biology models of various diseases in order to efficiently develop new therapeutic interventions and reduce the current prohibitively large costs of drug discovery.The section welcomes studies on the development of Biomedical Informatics for translational medicine and clinical applications, including tools, methodologies and data integration.

Introducing the Cardiovascular, metabolic and lipoprotein translation section of journal of translational medicine

Introducing the Cardiovascular, metabolic and lipoprotein translation section of journal of translational medicine.

New section in journal of translational medicine: patient-targeted molecular therapies

This Editorial announces a new section in the Journal of Translational Medicine: Patient-Targeted Molecular Therapies. This section is dedicated to the dissemination of targeted molecular therapies in context of patient-centered outcomes research and evidence-based clinical decisions. The focus on patient-targeted molecular therapies – spanning small molecules and biomolecules alike – stems from the unprecedented growth in this arena. This is consonant with the overall objective of the Journal of Translational Medicine, which seeks out to expand firmly to other vast areas of medicine in the domain of translational science, viewed here as the transaction between translational research and translational effectiveness. As we inaugurate this new section in Journal of Translational Medicine, with its mission described in detail in this Editorial, we invite interested scientists to submit their work for publication.

Expanding the perspective of translational medicine: the value of observational data

In 2003, the Journal of Translational Medicine was launched to foster the publication of high quality research in both "bench-to-bedside" as well as ex vivo human observation. In spite of the success of several large-scale observational studies, e.g. Framingham Heart Study, the opportunity to expand upon the ex vivo human observation has remained limited within the field of translational medicine. We believe that this presents a significant opportunity that merits consideration in both the planning and analysis of large scale observational studies and can contribute greatly to expanding our approaches in translational medicine

Supporting the advancement of science: Open access publishing and the role of mandates

In December 2011 the United States House of Representatives introduced a new bill, the Research Works Act (H.R.3699), which if passed could threaten the public's access to US government funded research. In a digital age when professional and lay parties alike look more and more to the online environment to keep up to date with developments in their fields, does this bill serve the best interests of the community? Those in support of the Research Works Act argue that government open access mandates undermine peer-review and take intellectual property from publishers without compensation, however journals like Journal of Translational Medicine show that this is not the case. Journal of Translational Medicine in affiliation with the Society for Immunotherapy of Cancer demonstrates how private and public organisations can work together for the advancement of science.